Beyond cyclosporine: A systematic review of limited sampling strategies for other immunosuppressants

Therapeutic Drug Monitoring

Volumn 28, Issue 3, 2006, Pages 419-430

  Ting, Lillian S L ^a   Villeneuve, Eric ^a   Ensom, Mary H H ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

Author keywords

Immunosuppressants; Limited sampling strategies; Mycophenolate; Systematic review; Tacrolimus

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ACCURACY; AREA UNDER THE CURVE; BAYES THEOREM; BLOOD SAMPLING; CITATION ANALYSIS; DRUG EXPOSURE; DRUG FORMULATION; DRUG MONITORING; ENVIRONMENTAL FACTOR; HEALTH CARE COST; HEREDITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MEDICAL DECISION MAKING; MEDICAL RESEARCH; METHODOLOGY; MULTIPLE REGRESSION; ORGAN TRANSPLANTATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RATING SCALE; REVIEW; SAMPLING; SYSTEMATIC REVIEW; UNITED STATES; VALIDATION PROCESS;

AREA UNDER CURVE; BAYES THEOREM; CYCLOSPORINE; DRUG MONITORING; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MODELS, BIOLOGICAL; MYCOPHENOLIC ACID; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; TACROLIMUS;

EID: 33748124928     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000211810.19935.44     Document Type: Review

References (50)

1. Kaplan B, MeierKriesche HU, Napoli K, et al. A limited sampling strategy for estimating sirolimus area-under-the-concentration curve. Clin Chem. 1997;43:539-540.
2. Moore MJ, Bunting P, Yuan SH, et al. Development and validation of a limited sampling strategy for 5-fluorouracil given by bolus intravenous administration. Ther Drug Monit. 1993;15:394-399.
3. Kong FH, Gonin R. Optimal sampling times in bioequivalence tests. J Biopharm Stat. 2000;10:31-44.
4. Guidance for Industry, Statistical Approaches to Establishing Bioequivalence. US Department of Health and Human Services. Rockville, MD: Food and Drug Administration; 2001:1-45.
5. Suarez-Kurtz G, Ribeiro FM, Vicente FL, et al. Development and validation of limited-sampling strategies for predicting amoxicillin pharmacokinetic and pharmacodynamic parameters. Antimicrob Agents Chemother. 2001;45:3029-3036.
6. Jackson AJ. Evaluation of a limited sampling method used to determine the bioequivalence of highly variable drugs with long half-lives. Biopharm Drug Dispos. 2001;22:179-190.
7. Suarez-Kurtz G, Ribeiro FM, Salvadori MC, et al. Carbamazepine: a bioequivalence study and limited sampling modeling. Int J Clin Pharmacol Ther. 2002;40:424-430.
8. Panchagnula R, Sancheti P, Rungta S, et al. Evaluation of bioequivalence of isoniazid and pyrazinamide in three and four drugs fixed dose combinations using WHO simplified protocol. Pharmacol Res. 2003;48:383-387.
9. David OJ, Johnston A. Limited sampling strategies for estimating cyclosporin area under the concentration-time curve: review of current algorithms. Ther Drug Monit. 2001;23:100-114.
10. Dumont RJ, Ensom MHH. Methods for clinical monitoring of cyclosporin in transplant patients. Clin Pharmacokinet. 2000;38:427-447.
11. Monchaud C, Rousseau A, Leger F, et al. Limited sampling strategies using Bayesian estimation or multilinear regression for cyclosporin AUC(0-12) monitoring in cardiac transplant recipients over the first year post-transplantation. Eur J Clin Pharmacol. 2003;58:813-820.
12. del Prado JMA, Rubio A, Aranzana MC, et al. New strategies of cyclosporine monitoring in heart transplantation: Initial results. Transplant Proc. 2003;35:1984-1987.
13. Jaiswal J, Gupta SK, Dash SC, et al. Neoral monitoring by limited sampling area under the concentration time curve in stable Indian renal transplant recipients. Transplant Proc. 2003;35:1298-1299.
14. Balram C, Sivathasan C, Cheung YB, et al. A limited sampling strategy for the estimation of 12-hour neoral systemic drug exposure in heart transplant recipients. J Heart Lung Transplant. 2002;21:1016-1021.
15. Filler G, Mai I. Limited sampling strategy for mycophenolic acid area under the curve. Ther Drug Monit. 2000;22:169-173.
16. Schutz E, Armstrong VW, Shipkova M, et al. Limited sampling strategy for the determination of mycophenolic acid area under the curve in pediatric kidney recipients. Transplant Proc. 1998;30:1182-1184.
17. Rousseau A, Marquet P. Application of pharmacokinetic modelling to the routine Ther Drug Monit of anticancer drugs. Fundam Clin Pharmacol. 2002;16:253-262.
18. Vanwarmerdam LJC, Huinink WWT, Maes RAA, et al. Limited-sampling models for anticancer agents. J Cancer Res Clin Oncol. 1994;120:427-433.
19. Mahmood I, Miller R. Comparison of the Bayesian approach and a limited sampling model for the estimation of AUC and C-max: a computer simulation analysis. Int J Clin Pharmacol Ther. 1999;37:439-445.
20. Sallas WM. Development of limited sampling strategies for characteristics of a pharmacokinetic profile. J Pharmacokinet Biopharm. 1995;23:515-529.
21. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981;9:503-512.
22. van Kersteren C, Mathot RAA, Lopez-Lazaro L, et al. A comparison of limited sampling strategies for prediction of ecteinascidin 743 clearance when administered as a 24-h infusion. Cancer Chemother Pharmcol. 2001;48:459-466.
23. Fukudo M, Yano I, Fukatsu S, et al. Forecasting of blood tacrolimus concentrations based on the Bayesian method in adult patients receiving living-donor liver transplantation. Clin Pharmacokinet. 2003;42:1161-1178.
24. Willis C, Taylor PJ, Salm P, et al. Evaluation of limited sampling strategies for estimation of 12-hour mycophenolic acid area under the plasma concentration-time curve in adult renal transplant patients. Ther Drug Monit. 2000;22:549-554.
25. Le Guellec C, Bourgoin H, Buchler M, et al. Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in stable renal transplant patients. Clin Pharmacokinet. 2004;43:253-266.
26. Le Guellec C, Buchler M, Giraudeau B, et al. Simultaneous estimation of cyclosporin and mycophenolic acid areas under the curve in stable renal transplant patients using a limited sampling strategy. Eur J Clin Pharmacol. 2002;57:805-811.
27. Ghio L, Ferraresso M, Vigano SM, et al. Mycophenolate mofetil pharmacokinetic monitoring in pediatric kidney transplant recipients. Transplant Proc. 2005;37:856-858.
28. Suarez-Kurtz G, Estrela RDC, Salvadori MC. Prednisolone-limited sampling strategies for estimating pharmacokinetic parameters. Ther Drug Monit. 2004;26:16-22.
29. Willis C, Staatz CE, Tett SE. Bayesian forecasting and prediction of tacrolimus concentrations in pediatric liver and adult renal transplant recipients. Ther Drug Monit. 2003;25:158-166.
30. Staatz CE, Willis C, Taylor PJ, et al. Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. Clin Pharmacol Ther. 2002;72:660-669.
31. Kovarik JM, Kahan BD, Kaplan B, et al. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine. Clin Pharmacol Ther. 2001;69:48-56.
32. Baraldo M, Isola M, Feruglio MT, et al. Therapeutic mycophenolic acid monitoring by means of limited sampling strategy in orthotopic heart transplant patients. Transplant Proc. 2005;37:2240-2243.
33. Pawinski T, Hale M, Korecka M, et al. Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus. Clin Chem. 2002;48:1497-1504.
34. Payen S, Zhang D, Maisin A, et al. Population pharmacokinetics of mycophenolic acid in kidney transplant pediatric and adolescent patients. Ther Drug Monit. 2005;27:378-388.
35. Johnson AG, Rigby RJ, Taylor PJ, et al. The kinetics of mycophenolic acid and its glucuronide metabolite in adult kidney transplant recipients. Clin Pharmacol Ther. 1999;66:492-500.
36. Premaud A, Le Meur Y, Debord J, et al. Maximum a posteriori bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods. Ther Drug Monit. 2005;27:354-361.
37. van Hest RM, Mathot RA, Vulto AG, et al. Mycophenolic acid in diabetic renal transplant recipients: pharmacokinetics and application of a limited sampling strategy. Ther Drug Monit. 2004;26:620-625.
38. Cho EK, Han DJ, Kim SC, et al. Pharmacokinetic study of mycophenolic acid in Korean kidney transplant patients. J Clin Pharmacol. 2004;44:743-750.
39. Filler G. Abbreviated mycophenolic acid AUC from C0, C1, C2, and C4 is preferable in children after renal transplantation on mycophenolate mofetil and tacrolimus therapy. Transpl Int. 2004;17:120-125.
40. Weber LT, Schutz E, Lamersdorf T, et al. Therapeutic drug monitoring of total and free mycophenolic acid (MPA) and limited sampling strategy for determination of MPA-AUC in paediatric renal transplant recipients. Nephrol Dial Transplant. 1999;14:34-35.
41. Yeung S, Tong KL, Tsang WK, et al. Determination of mycophenolate area under the curve by limited sampling strategy. Transplant Proc. 2001;33:1052-1053.
42. Dansirikul C, Staatz CE, Duffull SB, et al. Sampling times for monitoring tacrolimus in stable adult liver transplant recipients. Ther Drug Monit. 2004;26:593-599.
43. Balbontin FG, Kiberd B, Squires J, et al. Tacrolimus monitoring by simplified sparse sampling under the concentration time curve. Transplant Proc. 2003;35:2445-2448.
44. Jorgensen K, Povlsen J, Madsen S, et al. C2 (2-h) levels are not superior to trough levels as estimates of the area under the curve in tacrolimus-treated renal-transplant patients. Nephrol Dial Transplant. 2002;17:1487-1490.
45. Ku YM, Min DI. An abbreviated area-under-the-curve monitoring for tacrolimus in patients with liver transplants. Ther Drug Monit. 1998;20:219-223.
46. Kuypers DRJ, Claes K, Evenepoel P, et al. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids. A prospective study in one hundred de novo renal transplant recipients. Clin Pharmacokinet. 2004;43:741-762.
47. Rubio A, Arizon del Prado JM, Lopez Malo de Molina MD, et al. Clinical pharmacokinetics of tacrolimus in heart transplantation: new strategies of monitoring. Transplant Proc. 2003;35:1988-1991.
48. Wong KM, Shek CC, Chau KF, et al. Abbreviated tacrolimus area-under-the-curve monitoring for renal transplant recipients. Am J Kidney Dis. 2000;35:660-666.
49. Filler G, Feber J, Lepage N, et al. Universal approach to pharmacokinetic monitoring of immunosuppressive agents in children. Pediatr Transplant. 2002;6:411-418.
50. Mardigyan V, Tchervenkov J, Metrakos P, et al. Best single time points as surrogates to the tacrolimus and mycophenolic acid area under the curve in adult liver transplant patients beyond 12 months of transplantation. Clin Ther. 2005;27:463-469.